Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immune Checkpoint Inhibitor Rechallenge in Combination With Siltuximab Prophylaxis for Patients Who Had Prior Immune-Related Adverse Event (CIRES Trial)

NCT06470971 is registered in ClinicalTrials.gov with Yuanquan Yang as lead sponsor.

NCT NCT06470971
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06470971 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immune Checkpoint Inhibitor Rechallenge in Combination With Siltuximab Prophylaxis for Patients Who Had Prior Immune-Related Adverse Event (CIRES Trial)
Lead sponsor
Yuanquan Yang
Phase
Phase 2
Overall status
Recruiting
Start date
July 9, 2024
Completion date
December 31, 2030
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid neoplasm, hematopoietic and lymphatic system neoplasm